Overview

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

Status:
NOT_YET_RECRUITING
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor.
Phase:
PHASE1
Details
Lead Sponsor:
MediLink Therapeutics (Suzhou) Co., Ltd.
Collaborator:
Akesobio